In March 2025, Juventas Cell Therapy Ltd. conducted a phase Ib/II trial to evaluate the safety and efficacy of CNCT19 ...

Insights from analysts' 12-month price targets are revealed, presenting an average target of $28.56, a high estimate of ...

During a live event, Catherine J. Lee, MD, MS, discussed the mechanism of action of approved therapies for chronic ...

Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and ...

Apollomics and LaunXP have signed an agreement to develop and commercialise the former’s c-Met inhibitor vebreltinib.

AstraZeneca’s Calquence (acalabrutinib) in combination with bendamustine and rituximab has been recommended for approval in the European Union (EU) for the treatment of adult patients with previously ...

文章报道了细菌鞭毛蛋白特异性受体TLR5在围产期及新生小鼠的脑膜巨噬细胞上特异性高表达, 并且揭示了TLR5激活对于新生小鼠抵抗细菌性脑膜炎感染的作用, 为神经系统巨噬细胞功能性分区的进一步研究提供了借鉴。

Over 10 days, the porcine liver produces bile and porcine albumin, maintains stable blood flow, and shows no signs of ...

Research found that following a ketogenic diet for 6 months can reprogram immune cell metabolism and promote ...

A genetically modified porcine liver has been successfully transplanted into a human subject, constituting a historic ...

Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, today ...